7 Devonshire Square
DX136546 Bishopgate 2
We are pleased to invite you to a special workshop for senior in-house counsel of global life sciences companies, aimed at identifying current issues and comparing best practices in global antitrust compliance and to discuss recent related legal trends in the US, Europe and Asia (e.g., on patent settlement agreements).
The complimentary afternoon event, being held by us in conjunction with economic and legal experts from Brick Court Chambers and NERA Economic Consulting, will provide a better understanding of the nuances of antitrust law in the life sciences sector, as well as the context of these laws across the globe.
Many features of the life sciences sector make it prone to antitrust scrutiny. Intellectual property rights, in particular patents, and the promise of monopoly rents while patents remain valid play a crucial role in incentivising product research and development. On the other hand, enforcers and courts have applied antitrust laws to ensure that common product life cycle management strategies are not used to unduly prevent or delay generic entry or result in excessive and unfair prices.
Our expert panel, who will share insights and guidance in this area, includes:
- Robert O’Donoghue QC and Kelyn Bacon QC (Brick Court Chambers), who have advised Pfizer and Flynn Pharma, respectively, in connection with the recent Phenytoin Sodium case, which is the first case in the pharmaceutical sector in which pricing for a patented drug has been sanctioned as abusively excessive.
- Professor Frank Maier-Rigaud (NERA Economic Consulting), who, while at DG Competition, worked on the pharmaceutical sector inquiry and on some of the pay for delay cases of the European Commission, and has published extensively on the topic.
- Partners Mark Botti and Brian Hartnett, who co-lead our Competition-Antitrust Practice, joined by partner Diarmuid Ryan, along with partner Francesco Liberatore, who has advised AstraZeneca in connection with the Losec case, which is the first case in which the misuse of patent and regulatory procedures in the pharmaceutical sector has been regarded as an abuse of dominant position.
We hope you can join us with peers from across the industry for an informative and interactive discussion of these dynamic issues that continue to grow in importance.
This session is eligible for 3 CPD hours. Participants should refer to their profession’s regulation on CPD.